1 To date no study has described the cardiovascular eects of increased myo®lament Ca 2+ responsiveness in awake animals both under resting conditions and during treadmill exercise. In the present study we therefore investigated the systemic, pulmonary and coronary haemodynamic actions of the Ca 2+ sensitizer EMD 57033 in 16 chronically instrumented awake pigs at rest and during treadmill exercise, and compared these to the haemodynamic actions of the Ca 2+ sensitizer/phosphodiesterase inhibitor pimobendan. 2 Under resting conditions EMD 57033 (0.2, 0.4 and 0.8 mg kg 71 min 71 , i.v.) produced dosedependent increases in LVdP/dt max (up to 65+17% (mean +s.e.mean), P40.05) and stroke volume (up to 20+3%, P40.05), with an increase in heart rate only after the highest dose (22+5%, P40.05), while mean aortic blood pressure and LVdP/dt min were not altered. EMD 57033 had also no eect on pulmonary vascular resistance, but produced dose-dependent decreases in systemic vascular resistance (32+4%, P40.05), and coronary vascular resistance (44+2%, P40.05). These eects were essentially unchanged when animals were pretreated with non-selective b-adrenoceptor blockade, indicating that phosphodiesterase inhibition did not contribute to the positive inotropic actions of EMD 57033. 3 During exercise at 2, 3, and 4 km h 71 , the positive inotropic actions of EMD 57033 gradually waned at higher levels of exercise. This may have been caused by the exercise-induced increase in b-adrenergic activity, because after pretreatment with propranolol the positive inotropic actions of EMD 57033 were preserved at all levels of exercise. In contrast, the positive inotropic and chronotropic eects of pimobendan were ampli®ed during exercise, but were abolished (at rest) or markedly attenuated (during exercise) after pretreatment with propranolol. 4 The responses to EMD 57033 during exercise after combined a-and b-adrenergic receptor blockade were not dierent from those after b-adrenergic receptor blockade alone, indicating that the positive inotropic actions of EMD 57033 were not mediated via or did not depend on intact a-adrenergic receptor activity. 5 In conclusion, EMD 57033 increases left ventricular myocardial contractility in awake pigs. During exercise this eect is partially oset by the increased b-adrenergic activity, with no eect of a-adrenergic activity, suggesting that EMD 57033 may be most eective in patients with severe loss of b-adrenergic responsiveness.
Introduction
Inotropic pharmacotherapy of heart failure has traditionally included glycosides and sympathomimetic drugs. These compounds act by increasing intracellular Ca 2+ levels via inhibition of the Na + /K + ATPase or increased cAMP levels (phosphodiesterase inhibitors, b-adrenoceptor agonists and adenylyl cyclase activators), respectively. Untoward sideeects of increased cytosolic Ca 2+ levels include increased oxygen consumption and increased risk of arrhythmias (Katz, 1986) . Moreover, in patients with impaired left ventricular pump function b-adrenergic receptor responsiveness is often decreased (Bristow et al., 1982; 1986) , thereby attenuating the ecacy of particularly the sympathomimetic agents (Colucci et al., 1988; van der Giessen et al., 1989) . Over the past 15 years a class of drugs has emerged that stimulates cardiac contractile force at least in part by increasing the Ca 2+ sensitivity and, to a lesser extent, maximum Ca 2+ -induced contractile force of myocardial contractile proteins. The potential advantage of these`Ca 2+ sensitisers' could lie in their ability to increase contractile force without increasing energy consuming Ca 2+ transients (Holubarsch et al. 1989; Gross et al., 1993) . Moreover it is possible that these drugs are less susceptible to impairment of the b-adrenoceptor-adenylyl cyclase system than the phosphodiesterase inhibitors.
Putative Ca 2+ sensitisers include sulmazole, pimobendan, MCI-154, levosimendan and EMD 53998, all of which exert signi®cant additional PDE-III inhibitory actions (Ruegg & Solaro, 1993; Kubo, 1994; Haikala and LindeÂ n, 1995) , and EMD 60263 (Ravens et al., 1996) . EMD 53998 is a racemate consisting of (7)EMD 53998 (i.e. EMD 57439, a pure PDE III inhibitor) and (+) EMD 53998 (i.e. EMD 57033), a Ca 2+ sensitiser with minimal PDE III inhibitory actions in vitro (Ventura et al., 1992; Lues et al., 1993) . Data on the cardiovascular actions of EMD 57033 in vivo are lacking. Consequently, the present study was performed to investigate the systemic, pulmonary and coronary haemodynamic actions of EMD 57033 in chronically instrumented awake pigs and to compare these to the previously reported actions of pimobendan in the same model (Duncker et al., 1987a) . To determine the contribution of PDE III inhibition to the cardiostimulatory actions of EMD 57033, we also administered the same dose regimen in animals pretreated with the non-selective b-adrenergic receptor antagonist propranolol.
Abnormalities in left ventricular pump function of patients are often exacerbated or may become apparent only during increased physical activity. Therefore, it is important to study novel inotropic therapies not only under resting conditions but also during exercise. Consequently, we performed an additional set of experiments to study the cardiovascular eects of EMD 57033 during graded treadmill exercise and compared its actions to those of pimobendan. The contribution of PDE III inhibition to the actions of these compounds during treadmill exercise was evaluated by studying the eect of these agents after pretreatment with b-adrenergic receptor blockade. Finally, to exclude the possibility that the EMD 57033-induced increase in Ca 2+ responsiveness was mediated by a-adrenoceptors (Endoh & Blinks, 1988; Terzic et al., 1992) , we studied the eects of EMD 57033 on left ventricular performance at rest and during treadmill exercise in the presence of combined a-and b-adrenergic blockade.
Methods
A total number of 16 crossbred Landrace 6 Yorkshire pigs (24+1 kg) of either sex were used in the present study. All experiments were performed in accordance with the`Guiding Principles in the Care and Use of Laboratory Animals' as approved by the Council of the American Physiological Society and with the prior approval of the Animal Care Committee of the Erasmus University Rotterdam. Adaptation of animals to the laboratory conditions started 1 week prior to the day of surgery and continued until 1 week after surgery.
Surgical procedures
After an overnight fast, pigs were sedated with ketamine (30 mg kg 71 i.m.; Ketalin1, Apharmo BV, Arnhem, The Netherlands), anaesthetised with thiopental (15 mg kg 71 , i.v.; Nesdonal1, Rhone-Poulenc Rorer BV, Amstelveen, The Netherlands), intubated and mechanically ventilated with a mixture of oxygen and nitrous oxide (1 : 2) to which 0.2 ± 1% iso¯urane (Forene1, Abbott BV, Amstelveen, The Netherlands) was added. Anaesthesia was maintained with midazolam (2 mg kg 71 + 0.5 mg kg 71 h 71 , i.v.; Dormicum1, Roche BV, Mijdrecht, The Netherlands) and fentanyl (10 mg kg 71 + 10 mg kg 71 h 71 , i.v.; Fentanyl-Janssen1, Janssen-Cilag BV, Tilburg, The Netherlands). Under sterile conditions, the chest was opened via the fourth left intercostal space and an 8 French (F)¯uid-®lled polyvinylchloride (PVC) catheter was inserted into the aortic arch, for the measurement of central aortic blood pressure, and secured with a purse string suture. After the pericardium was opened, an electromagnetic¯ow probe (Skalar, Delft, The Netherlands) was positioned around the ascending aorta for measurement of aortic blood¯ow. A high ®delity pressure transducer (Konigsberg Instruments Inc., Pasadena, CA, U.S.A.) was inserted into the left ventricle (LV) via the apical dimple for recording of LV pressure and its ®rst derivative (LVdP/dt; obtained via electrical dierentiation). An 8 F PVC catheter was also inserted into the LV for calibration of the Konigsberg transducer signal. Similar catheters were introduced into the left atrium and into the pulmonary artery for the measurement of blood pressure and administration of drugs. A Doppler¯ow probe (2.0 or 2.5 mm in diameter, emitting frequency (f 0 ) = 20 MHz; Crystal Biotech, Northboro, MA, U.S.A.) was placed around the proximal part of the left anterior descending coronary artery to measure the coronary blood¯ow. Electrical wires and catheters were tunnelled subcutaneously to the back, the chest was closed and the animals allowed to recover. All electrical wires and catheters were protected with a vest (Tubigrip1, Seton Healthcare Group, Oldham, U.K.).
Post-surgical period
During the ®rst 48 hours after surgery animals received pain treatment consisting of buprenorphine (0.3 mg, i.v., once daily; Temgesic1, Reckitt and Colman Products, Kingston-uponHull, U.K.). During the ®rst week after surgery animals received intravenous injections of 25 mg kg 71 amoxicillin (Clamoxil1, Beecham Farma B.V., Amstelveen, The Netherlands) and 5 mg kg 71 gentamycin (Gentamycine 5%1, A.U.V., Cuijk, The Netherlands) on a daily basis to prevent infection. Catheters were¯ushed daily with physiologic saline containing 2000 IU ml 71 heparin. 
Experimental protocols
Haemodynamic responses to EMD 57033 in awake resting swine Resting studies were performed in a total of 11 pigs at 1 ± 2 weeks after surgery with animals lying unrestrained in a cage. All resting studies were performed in random order at a minimum interval of 24 h. 1. Solvent. Systemic, pulmonary and coronary haemodynamic responses to propylene glycol (the solvent of EMD 57033) were studied in 10 resting pigs. After baseline haemodynamic measurements had been recorded, animals received three consecutive 10 min i.v. infusions of solvent administered at rates of 0.5, 1.0 and 2.0 ml min
71
, respectively. Haemodynamic measurements were made at the end of each infusion period and during the subsequent two hour washout period. 2. EMD 57033. The haemodynamic eects of three consecutive 10 min intravenous infusions of EMD 57033 in doses of 0.2, 0.4 and 0.8 mg kg 71 were studied in 10 pigs. Data were collected at the end of each infusion period and during the subsequent 2 h washout period. 3. EMD 57033 in the presence of b-adrenergic receptor blockade. After baseline haemodynamic measurements had been made, 10 pigs received a slow intravenous injection of propranolol (0.5 mg kg 71 ) followed by an infusion (0.5 mg kg 71 h 71 , i.v.). This dose regimen results in 495% inhibition of isoproterenol-induced increases in heart rate and LVdP/dt max in awake swine (Duncker et al., 1987b) . Ten minutes later, the post-propranolol data were recorded and the EMD 57033 infusion protocol (0.2, 0.4 and 0.8 mg kg 71 min 71 , i.v.) performed.
Eects of EMD 57033 and pimobendan on the haemodynamic responses to graded treadmill exercise Studies were performed in 14 pigs at 2 ± 4 weeks after surgery with animals exercising on a motor driven treadmill. All exercise protocols were performed in random order at a minimum interval of 24 h. , i.v., n=8). Five minutes later resting measurments were obtained and the exercise protocol was repeated. 3. EMD 57033 in the presence of combined a-and b-adrenergic receptor blockade. In seven swine we studied the eects of combined a-and b-adrenergic receptor blockade on haemo- dynamic responses to EMD 57033 during treadmill exercise. For this purpose, animals received propranolol (0.5 mg kg 71 , i.v.) and phentolamine (1.0 mg kg 71 , i.v.) ; the dose of phentolamine results in 495% inhibition of the noradrenaline (0.3 mg kg 71 , intracarotid) induced increase in carotid vascular resistance in anaesthetized swine (Verdouw et al., 1984) . Ten minutes later, resting measurements were made with animals both lying and standing followed by the 3-stage exercise protocol as described above. After completion of all measurements, animals were allowed to rest for 60 min. Then, animals received propranolol (0.2 mg kg 71 , i.v.) and phentolamine (0.4 mg kg 71 , i.v.) followed by either no treatment (control, n=7) or EMD 57033 (0.4 mg kg 71 min 71 , i.v., n=7). Five minutes later resting measurements were obtained and the exercise protocol was repeated.
Data acquisition and analysis
Data were recorded and digitized on-line using an eight channel data-acquisition program ATCODAS (Dataq Instruments, Inc., Akron Ohio, U.S.A.) and stored on a computer for later post-acquisition o-line analysis with a program written in MatLab (The Mathworks Inc., Mass, U.S.A.). A minimum of 15 consecutive beats were selected for analysis of the digitised haemodynamic signals. From these the heart rate, LV peak systolic, LV end-diastolic, mean left atrial, mean aortic, and mean pulmonary artery pressures, LVdP/dt max , LVdP/dt min , aortic blood¯ow and the mean coronary Doppler shift were determined.
Mean coronary blood¯ow was computed from the mean Doppler shift using the equation Q=1.25.Df.d 2 , where Q is the coronary blood¯ow (ml min 71 ), Df is the Doppler shift (KHz), d is the internal diameter of the coronary artery (mm) within the¯ow probe (Ishida et al., 1983) . The factor 1.25 is a constant derived from the speed of sound in tissue (C=1.5 10 5 cm s 71 ), the frequency of the emitted sound beam (f 0 =20 MHz), the cosine of the angle at which the sound beam is emitted (458C), and unit conversion factors: (C.0.75 p) / (2f 0 .cos 458C). As in chronically instrumented animals thē ow probe is tightly adherent to the coronary artery, the internal diameter of the¯ow probe is equal to the external diameter of the artery. To obtain the inner diameter of the coronary artery we subtracted 10% of the external diameter of the coronary artery, which is approximately the arterial wall thickness. In this way any error in computation of the coronary internal diameter would aect control and intervention conditions equally.
Cardiac output was computed as ascending aorta¯ow (measured with the electromagnetic¯ow probe)+2.5.coronary blood¯ow (as the left anterior descending coronary artery supplies approximately 40% of the LV). Systemic vascular resistance was computed as the ratio of mean aortic pressure and cardiac output; pulmonary vascular resistance was calculated as the ratio of the mean pulmonary artery pressure7mean left atrial pressure dierence and cardiac output; coronary vascular resistance was computed as the ratio of mean aortic pressure and coronary blood¯ow. Stroke volume was calculated as the ratio of cardiac output and heart rate, while myocardial work was de®ned as the product of cardiac output and LV peak systolic blood pressure.
Statistical analysis of the resting protocols was performed using one-way analysis of variance for repeated measures. When a signi®cant eect was observed post-hoc testing was done using Dunnett's test. To compare the changes between the three resting protocols two-way (dose and treatment) analysis of variance for repeated measures was performed. Statistical analysis of the exercise protocols was performed using two-way (exercise and treatment) analysis of variance for repeated measures. When a signi®cant eect of exercise was observed, one-way analysis of variance for repeated measures was performed followed by post-hoc testing with a paired t test. When a signi®cant eect of treatment was observed differences were tested using a paired t test. A P value of less than or equal to 0.05 was considered statistically signi®cant (twotailed). All data are presented as mean +s.e.mean.
Drugs
EMD 57033 (the (+) enantiomer of 5-[1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydro-6-quinolyl]-6-methyl-3,6-dihydro-2H-1,3,4-thiadiazin-2-one; courtesy of Dr P Schelling, E. Merck KGaA, Darmstadt, Germany) and pimobendan (courtesy of Dr J. DaÈ mmgen, Thomae, Biberach, Germany) were dissolved in 408C propylene glycol (Sigma Chemical Co, St Louis, MO, U.S.A.). Phentolamine (10 mg ml 71 , Regitine1, Ciba-Geigy BV, Arnhem, The Netherlands) was dissolved in water containing glucose (35 mg ml 71 ) and further diluted in saline to produce a ®nal concentration of 0.1 mg kg 71 ml 71 . Propranolol (Sigma Chemical Co, St Louis, MO, U.S.A.) was dissolved in 308C saline to produce a concentration of 0.05 mg kg 71 ml 71 . Fresh drug solutions were prepared on the day of each experiment.
Results
Haemodynamic responses to EMD 57033 in awake resting swine Solvent (Table 1 ) Intravenous infusion of the lower two doses of solvent had no systemic or coronary haemodynamic eects, but produced slight increases in pulmonary artery pressure (2+1 mmHg). The highest dose of solvent (2 ml min 71 ) also produced slight increases in LV ®lling pressure (4+1 mmHg) resulting in an increase in stroke volume (10+3%) and hence cardiac output (15+4%), and a small decrease in systemic vascular resistance (11+4%), but had no eect on LVdP/dt max . Upon termination of infusion of the highest rate of solvent, all variables returned to baseline values within 15 min, with the exception of cardiac output and pulmonary artery pressure which had returned to baseline at 30 min (data not shown).
EMD 57033 in the absence and presence of b-adrenergic receptor blockade 1. Systemic haemodynamics (Figure 1 ). EMD 57033 produced a dose-dependent increase in cardiac output (up to 41+6%; P40.01 vs solvent-induced increase), which was principally due to an increase in stroke volume at lower doses while a modest increase in heart rate (22+5%, P40.01) contributed during the highest dose. The increase in stroke volume resulted most likely from an increase in contractility (re¯ected by a 65+17% increase in LVdP/dt max during infusion of the highest dose; P40.01 vs solvent) as LV end-diastolic pressure was minimally elevated (3+1 mmHg, P=NS vs 4+1 mmHg increase by solvent), while LV systolic pressure increased slightly (P40.05 vs solvent.). Despite the increase in cardiac output, EMD 57033 had no eect on mean aortic blood pressure, implying that systemic vascular resistance had decreased (32+4%, P40.01 vs solvent). EMD 57033 had no signi®cant eect on LVdP/dt min although the trend towards a decrease may not have reached statistical signi®cance at the highest dose (P=0.12) due to the EMD 57033-induced increase in LV systolic pressure. Fifteen minutes after the infusion was terminated, all haemodynamic variables had returned The maximum rate of rise of LV pressure (LVdP/dt max ) data have been plotted as a function of heart rate (HR). Data are mean+s.e.mean; n=14, 12, 9, 9, 9, 8 for a ± f, respectively. *P40.05 vs corresponding control conditions (®rst exercise period), {P40.05 vs corresponding change in the absence of b-adrenoceptor blockade.
to baseline values, with the exception of LVdP/ max which was still 26+7% higher than at baseline and LVdP/dt min which had decreased to 17+4% below baseline (both P40.05 vs solvent). At 60 min after the infusion had been stopped, LVdP/dt min had returned to baseline, but LVdP/dt max remained elevated above baseline (30+7% and 32+5% at 1 and 2 h, respectively, both P40.05 vs solvent) during the entire 2 h washout period (data not shown).
b-adrenergic receptor blockade with propranolol resulted in signi®cant reductions in heart rate (7+2%), LVdP/dt max (21+5%) and cardiac output (9+3%) and increases in LV end-diastolic pressure (22+6%) (all P40.01), but did not alter the EMD 57033-induced haemodynamic responses, except for a slight attenuation of the increases in heart rate (P40.05 vs EMD 57033 without propranolol) and LVdP/dt max (P=0.08 vs EMD 57033 without propranolol) produced by the highest dose. In addition, the highest dose of EMD 57033 produced a 5+2 mmHg increase in LV end-diastolic pressure (P40.05 vs baseline), but this increase was not dierent from 4+1 mmHg increase produced by the equivalent infusion rate of solvent. During washout, haemodynamic variables behaved similarly as in animals with intact b-adrenergic receptors, so that at 15 min washout LVdP/dt max was still 20+3% above and LVdP/dt min had decreased to 16+5% below pre-EMD 57033 baseline (both P40.05). Thirty minutes after the infusion was stopped, LVdP/dt min had returned to baseline, while LVdP/ dt max again remained elevated above baseline during the entire 2 h washout period, although this was slightly less pronounced (18+4% and 14+4% at 1 and 2 h, respectively, both P40.05) compared to animals with intact b-adrenoceptors. 2. Pulmonary haemodynamics (Figure 2) . EMD 57033 produced a dose-dependent increase in mean pulmonary artery pressure, which was the result of an increased mean left atrial pressure as well as an increase in cardiac output. Consequently, pulmonary vascular resistance did not change (P=NS vs baseline or solvent). Propranolol had no signi®cant eect on pulmonary vascular resistance and did also not alter the pulmonary haemodynamic responses to EMD 57033. Fifteen minutes after the infusion was stopped, all pulmonary haemodynamic variables had returned to baseline. 3. Coronary haemodynamics (Figure 3) . EMD 57033 produced a dose-dependent increase in coronary blood¯ow (up to 74+7% of baseline, P40.05 vs solvent), which could in part be explained by the 59+9% increase in the myocardial work (triple product of heart rate.stroke volume.LV systolic pressure). Propranolol caused a 9+2% (P40.05) decrease in coronary blood¯ow but did not alter the responses of coronary blood¯ow and vascular resistance to EMD 57033. Fifteen minutes after the infusion was stopped, all coronary heamodynamic variables had returned to baseline. to 7.3+0.4 1 min 71 (all P40.01). While mean aortic pressure did not change from rest lying, mean pulmonary artery pressure almost doubled from 15+1 to 29+2 mmHg (P40.01). These dierent pressure responses of the systemic and pulmonary vascular beds re¯ect the intense systemic vasodilation (54+1% decrease in systemic vascular resistance, P40.01) vs the unaltered pulmonary vascular resistance. Coronary blood¯ow increased from 33+4 ml min 71 at rest to 57+6 ml min 71 during the highest level of exercise. After 60 min of rest, at a time when all variables had returned to baseline levels, the second period of exercise resulted in highly reproducible systemic, pulmonary and coronary haemodynamic responses.
Eects of EMD
EMD 57033 ( Figure 4 ) and an increase in cardiac output from 3.9+0.2 to 4.3+0.2 l min 71 (P40.01) ( Table 3 ). In the presence of EMD 57033, exercise at 2 km h 71 resulted in a 9+4% higher LVdP/dt max (P=0.07) than during exercise under control conditions. However, at 3 and 4 km h 71 LVdP/dt max and cardiac output were no longer elevated compared to control exercise. The responses of LV systolic and mean aortic blood pressure to exercise in the presence of EMD 57033 were not dierent from their respective responses to control exercise. EMD 57033 decreased systemic vascular resistance at rest and during exercise at 2 km h 71 , but at 3 and 4 km h 71 systemic vascular resistance was no longer dierent from control exercise. In the presence of EMD 57033 exercise resulted in elevated pulmonary artery pressure and left atrial pressure compared to control exercise, but pulmonary vascular resistance was not dierent from control exercise. EMD 57033 produced coronary vasodilation resulting in higher coronary blood¯ows during exercise in the presence of EMD 57033 compared to control exercise, which could only in part be explained by the higher myocardial work loads. control exercise. Pimobendan had no signi®cant eect on pulmonary haemodynamics. Similar to EMD 57033, pimobendan produced higher coronary blood¯ows which in part paralleled the higher myocardial work loads.
Pimobendan (
Eects of EMD 57033 and pimobendan on the haemodynamic responses to graded treadmill exercise in the presence of b-adrenergic receptor blockade Control (Table 5 , Figures 4 and 5) b-adrenergic receptor blockade markedly blunted the exercise-induced increases in heart rate, LVdP/dt max , LV systolic pressure, cardiac output, and coronary blood¯ow compared to exercise with normal badrenergic activity. After 60 min of rest, when all variables had returned to baseline values, the second exercise period in the presence of b-adrenergic receptor blockade, resulted in highly reproducible systemic, pulmonary and coronary haemodynamic responses.
EMD 57033 (Table 6 , Figures 4 and 5) After pretreatment with b-adrenergic receptor blockade, exercise in the presence of EMD 57033 (0.4 mg kg 71 min 71 ) resulted in higher levels of LVdP/dt max and stroke volume compared to exercise in the presence of propranolol alone. After propranolol, EMD 57033 produced increases in pulmonary artery pressure at rest and during exercise which appeared to be the result of pulmonary vasoconstriction, but these eects were not signi®cantly different from the eects of solvent on pulmonary haemodynamics. During exercise in the presence of propranolol, the eects of EMD 57033 on coronary blood¯ow and vascular resistance were maintained.
Pimobendan (Table 7, Figures 4 and 5)
In the presence of badrenergic receptor blockade the increases in LVdP/dt max and stroke volume were abolished at rest and markedly attenuated during exercise, compared to control conditions, indicating that the cardiostimulatory actions of pimobendan depended on the degree of b-adrenoceptor activity. In contrast, the systemic vasodilator eects were unmitigated in the presence of propranolol at rest and during exercise. During b-adrenoceptor blockade pimobendan produced less coronary vasodilation at rest (in parallel with an unchanged myocardial work) but its vasodilatory actions were maintained during exercise.
Eects of EMD 57033 on the haemodynamic responses to graded treadmill exercise in the presence of combined a-and b-adrenergic receptor blockade Control (Figure 6 ) In the presence of combined a-and badrenergic receptor blockade exercise produced similar haemodynamic responses compared to exercise during single badrenergic receptor blockade, with the exception of a lower systemic vascular resistance and mean aortic pressure (data not shown). Two consecutive exercise periods in the presence of combined a-and b-adrenergic receptor blockade separated by 60 min of rest, resulted in highly reproducible systemic, pulmonary and coronary haemodynamic responses.
EMD 57033 (Figure 6 ) Combined a-and b-adrenergic receptor blockade did not alter the positive inotropic responses to EMD 57033 (0.4 mg kg 71 min 71 , i.v.) either at rest or during exercise indicating that the inotropic actions of EMD 57033 were not mediated via a-adrenoceptors. The coronary vasodilator response to EMD 57033 was also not further modi®ed by additional a-adrenergic receptor blockade, but the systemic vasodilator response was attenuated (data not shown).
Discussion
The present study describes the cardiovascular eects of the Ca 2+ sensitizer EMD 57033 in awake pigs, free from the eects of anaesthesia and acute surgical trauma, in which we previously studied the cardiovascular pro®le of the mixed Ca 2+ sensitizer/PDE-III inhibitor pimobendan (Duncker et al., 1987a) . The main ®ndings under resting conditions were: (1) EMD 57033 produced dose-dependent increases in global LV contractility and stroke volume, with a minimal eect on heart rate and blood pressure, and produced a decrease in systemic vascular resistance, (2) these eects were essentially unchanged when animals were pretreated with b-adrenoceptor blockade, indicating that phosphodiesterase inhibition does not contribute signi®cantly to the positive inotropic actions of EMD 57033. Furthermore, the present study demonstrated that during exercise (3) the positive inotropic actions of EMD 57033 persisted at low levels of exercise but were no longer observed at higher levels of exercise, which may have been caused by the exercise-induced increases in b-adrenergic activity and cAMP levels, because pretreatment with propranolol resulted in preservation of the positive inotropic actions at all levels of exercise; (4) in contrast, the positive inotropic and chronotropic eects of pimobendan were ampli®ed during exercise with intact b-adrenoceptors, but were abolished at rest and markedly blunted during exercise in the presence of badrenoceptor blockade, and (5) ®nally, combined a-and badrenergic receptor blockade did not further alter the responses to EMD 57033 during exercise, compared to the responses to EMD 57033 during b-adrenergic receptor blockade alone, indicating that the positive inotropic actions of EMD 57033 were not mediated via or did not depend on intact aadrenergic receptor activity.
Eects of EMD 57033 on systemic, pulmonary and coronary haemodynamics in awake resting pigs During resting conditions EMD 57033 produced dose-dependent increases in LVdP/dt max , stroke volume and cardiac output. These eects were only minimally aected by pretreatment with propranolol, suggesting that PDE inhibition contributed only minimally to the cardiostimulatory actions. Only during the highest dose did we observe an increase in heart rate which was blunted by pretreatment with propranolol suggesting that EMD 57033 produced slight phosphodiesterase inhibition at this dose (Nankervis et al., 1994) . In contrast, we previously observed that the pimobendan-induced increases in cardiac output, heart rate and LVdP/dt max were markedly attenuated by pretreatment with propranolol ( Figure 7 ; Duncker et al., 1987a) , indicating that this purported Ca 2+ sensitiser exerts a major part of its actions via phosphodiesterase inhibition in awake pigs. In awake dogs, another Ca 2+ sensitiser levosimendan also produced dose-dependent increases in LVdP/ dt max and cardiac output. Autonomic blockade with propranolol, atropine and hexamethonium, markedly attenuated (450%) the chronotropic and inotropic responses of even the lowest doses of levosimendan, suggesting that the cardiostimulatory actions were most likely the result of both PDE-III inhibition and Ca 2+ sensitization (Harkin et al., 1995) . Interestingly, the increase in cardiac output was entirely due to an increase in heart rate, with no change in stroke volume which may have resulted from the decrease in LV preload. These ®ndings with levosimendan in awake dogs are very similar to our data with pimobendan in awake normal pigs (Duncker et al., 1987a) . In healthy resting humans, levosimendan also increased cardiac output, which was due to an increase in stroke volume at a lower dose, while at a higher dose it resulted entirely from an increase in heart rate (Lilleberg et al., 1994; Sundberg et al., 1995) .
Although we failed to ®nd evidence to support a signi®cant contribution of phosphodiesterase inhibition to the actions by EMD 57033, direct evidence that the positive inotropic actions of EMD 57033 are mediated by an increase in responsiveness of the myo®laments to Ca 2+ has so far been obtained exclusively in in vitro studies. Thus, in isolated ferret hearts EMD 57033 at concentrations of 0.3 ± 10 mM increased the force of contraction despite a slight decrease in Ca 2+ transient, whereas its (7) enantiomer the phosphodiesterase inhibitor EMD 57439 increased the Ca 2+ transient together with an increase in contractile force (White et al., 1993) . In skinned ventricular ®bers isolated from guinea pig hearts EMD 57033 in concentrations of up to 3 ± 10 mM increased the Ca 2+ sensitivity of the myo®laments re¯ected by a decrease in the Ca 2+ concentration that results in 50% of the maximum response of the Ca 2+ -force relation (0.2 ± 0.5 log units increase in pCa 50 ) and increased the maximum contractile force by 10 ± 15% . Importantly, in concentrations lower than 10 mM EMD 57033 had minimal eects on isoprenaline-mediated production of cAMP, suggesting negligible eects on phosphodiesterase inhibiting activity at these concentrations. In support of the latter ®nding, the increase in contractile force in intact guinea pig papillary muscle produced by EMD 57033 was not aected by the presence of a low dose of the b-adrenoceptor agonist isoprenaline (which by itself increased basal contractile force by 15%). In contrast, the increase in force produced by EMD 57439 was markedly potentiated by the dose of isoprenaline . These ®ndings support our in vivo observations and provide, albeit indirect evidence that the positive inotropic actions observed in the present in vivo study are most likely mediated via an increase in Ca 2+ responsiveness (either an increase in sensitivity or maximum force) of the myo®laments.
To demonstrate that EMD 57033 also increases the myo®-lament responsiveness to Ca 2+ in vivo, we studied the eects of EMD 57033 on the regional myocardial contractile responses to intracoronary infusions of Ca 2+ in two pentobarbital anaesthetized open-chest pigs, in which b-adrenoceptor activity was blocked to exclude phosphodiesterase activity by EMD 57033. The animals were instrumented with an LV microtipped pressure transducer, a coronary Doppler¯ow probe around the left anterior descending coronary artery, and distal to the probe an intracoronary catheter for infusion of Ca 2+ . In the myocardium perfused by the left anterior descending coronary artery ultrasonic crystals were implanted for the measurement of End-Systolic Elastance (E ES ), the directional coecient of the LV end-systolic pressure segment relation, as a measure of regional myocardial contractile function (Krams et al., 1993) ; LV preload was varied by in¯ation of a balloon positioned in 2+ is enhanced by EMD 57033. The mechanism by which EMD 57033 induces these alterations in the interaction between Ca 2+ and the myo®laments is still incompletely understood. A favoured hypothesis is that EMD 57033 increases the sensitivity of troponin C to Ca 2+ (Pan & Johnson, 1996) , although modulation of the cooperative interaction between adjacent troponin-tropomyosin units along the thin ®laments or an eect on the cross-bridge kinetics may also contribute Lues et al., 1993) .
In view of its potential use in patients with LV dysfunction, the eects of EMD 57033 on LV ®lling pressure deserve comment. In resting pigs with intact b-adrenoceptor activity, EMD 57033 in a dose of 0.8 mg kg 71 min 71 increased LV end-diastolic pressure by 3+1 mmHg, while in the presence of b-adrenoceptor blockade, LV end-diastolic pressure was increased by 5+2 mmHg. Although this would appear to be an unfavourable eect, it is important to note that the equivalent rate of solvent infusion (2 ml min 71 ) produced a 4+1 mmHg increase in LV end-diastolic pressure. These ®ndings are best interpreted as a lack of an eect of EMD 57033 per se on LV ®lling pressure. However, EMD 57033 does not decrease LV ®lling pressure,which contrasts with the decrease in LV ®lling pressure observed in pigs during infusion of pimobendan (Duncker et al., 1987a) or the pure phosphodiesterase inhibitor amrinone (Hartog et al., 1986) . The increase in Ca 2+ responsiveness produced by EMD 57033 did not result in constriction of either the pulmonary or systemic vascular bed. The decrease in systemic vascular resistance could have resulted in part from withdrawal of aadrenergic tone to prevent an increase in aortic blood pressure secondary to the EMD 57033-induced increase in cardiac output. This is suggested by the observation that the decrease in resistance was attenuated in the presence of a-adrenergic blockade. It is also possible that systemic vasodilation resulted in part from PDE-III inhibition, although this would seem unlikely as pretreatment with b-adrenoceptor blockade did not alter the degree of systemic vasodilation. However, in vascular smooth muscle b-adrenoceptors are, unlike in the myocardium, not an exclusive source for cAMP production as adenosine (Olsson et al., 1991) and prostaglandins (Bassenge, 1995) also increase cAMP production, so that PDE-III inhibition could still have resulted in peripheral vasodilation even when b-adrenoceptors were blocked. Finally, there is some evidence that EMD 57033 can produce endothelium-dependent vasodilation, which may also have contributed to its vasodilator action in the present study (Nankervis et al., 1994) .
EMD 57033 increased coronary blood¯ow in excess of the increase in myocardial work. This action of EMD 57033 was not aected by pretreatment with either b-adrenoceptor blockade or combined a-and b-adrenoceptor blockade, suggesting that EMD 57033 produced at least in part direct coronary vasodilation possibly via release of endothelium derived substances (Nankervis et al., 1994) . In contrast, the coronary vasodilation produced by pimobendan under resting conditions was abolished after pretreatment with propranolol suggesting that the vasodilation resulted principally from an increase in myocardial work but possibly also from PDE-III inhibition.
Haemodynamic actions of EMD 57033 during treadmill exercise
An interesting ®nding in the present study was that the cardiostimulatory actions of EMD 57033 gradually waned when the work load was increased. Thus, in the presence of EMD 57033 exercise resulted in LVdP/dt max levels that were not dierent compared to control exercise. Similar ®ndings have been reported for levosimendan in healthy humans (Sundberg et al., 1995) . It is possible that exercise-induced increments in b-adrenergic activity, via cAMP-mediated phosphorylation of troponin-l, neutralizes the levosimendan or EMD 57033-mediated increases in Ca 2+ responsiveness of the myo®laments (Herzig et al., 1981) . In the present study, EMD 57033 produced an increase in contractility at all levels of exercise in the presence of b-adrenoceptor blockade, which is consonant with the hypothesis that during exercise in the normal heart a pharmacologically-induced increase in myo®lament sensitivity to Ca 2+ can be oset by very high levels of b-adrenergic activity. In contrast, the positive inotropic actions of pimobendan were enhanced at higher levels of exercise, but were markedly blunted during exercise in the presence of b-adrenoceptor blockade, ®ndings that are consistent with a predominantly PDE-III inhibitory action of pimobendan.
An alternative explanation could be that EMD 57033 increased Ca 2+ responsiveness via an a-adrenergic receptor dependent mechanism (Endoh & Blinks, 1988; Terzic et al., 1992) , so that with increasing exercise levels the progressively greater a-adrenergic receptor stimulation resulted in near maximal increments of myo®lament Ca 2+ responsiveness. As a result EMD 57033 could then have been unable to produce a further increase in Ca 2+ responsiveness via this mechanism. In the present study, EMD 57033 produced an increase in contractility at all levels of exercise in the presence of b-adrenoceptor blockade, while the addition of a-adrenoceptor blockade to the b-adrenoceptor blockade did not further alter this response. Thus, the positive inotropic responses to EMD 57033 were not mediated via a-adrenoceptor stimulation and did not depend on intact a-adrenoceptor activity.
The reduced eectiveness of EMD 57033 during higher levels of physical activity could limit the drug's usefulness in humans where abnormalities in cardiac pump function often become apparent only during exercise. It is important to note, however, that in patients with heart failure loss of b-adrenergic receptor responsiveness and density is correlated with the loss of LV pump function. The results from the present study suggest that those patients with the greatest impairment in function could bene®t the most from an increase in Ca 2+ responsiveness.
During exercise, EMD 57033 produced coronary vasodilation which resulted in an upward shift of the relation between myocardial work and coronary blood¯ow. This action was again not aected by pretreatment with either b-adrenoceptor blockade or combined a-and b-adrenoceptor blockade, suggesting that EMD 57033 produced at least in part direct coronary vasodilation. In contrast, the coronary vasodilation produced by pimobendan during exercise was attenuated after pretreatment with propranolol suggesting that it resulted from PDE-III inhibition. Importantly, the present study suggests that even when diastolic duration is reduced, such as during exercise-induced tachycardia, the positive inotropic actions of either EMD 57033 or pimobendan do not appear to compromise myocardial perfusion.
Conclusions
EMD 57033 results in dose-dependent increases of left ventricular contractility in awake pigs. This positive inotropic action is partially oset during exercise by the increased badrenergic activity, but occurs independently of a-adrenergic activity. These ®nding suggest that EMD 57033 will be most eective in patients with severe loss of b-adrenergic responsiveness. , n=10) and pimobendan (10, 25, 50 and 100 mg kg 71 min 71 , n=6) in the absence (7propranolol) and in the presence of b-adrenoceptor blockade (+propranolol) in awake resting swine. Data have been plotted as a function of the increase in heart rate (HR). Pimobendan data have been reported previously (Duncker et al., 1987a) .
